23/07/2021 (Agence Europe) – The European Medicines Agency (EMA) concluded on Friday 23 July that the use of the Spikevax Covid-19 vaccine developed by the company Moderna could be extended to children aged 12 to 17 years. A study of 3,732 young people found that the antibody response to Spikevax in 12-17 year olds was comparable to that seen in young adults aged 18-25 years. Spikevax is the second vaccine to be so recommended at the European level, following Pfizer/BioNTech’s...